# Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)

> **NCT05155293** · PHASE3 · COMPLETED · sponsor: **Alvotech Swiss AG** · enrollment: 413 (actual)

## Conditions studied

- Neovascular (Wet) AMD

## Interventions

- **DRUG:** AVT06 (proposed aflibercept biosimilar)
- **DRUG:** Eylea® (Aflibercept)

## Key facts

- **NCT ID:** NCT05155293
- **Lead sponsor:** Alvotech Swiss AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-28
- **Primary completion:** 2023-11-17
- **Final completion:** 2024-09-23
- **Target enrollment:** 413 (ACTUAL)
- **Last updated:** 2024-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05155293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05155293, "Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05155293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*